Form 4: Phathom Pharmaceuticals Director Receives RSUs

Phathom Pharmaceuticals, Inc. reports that Director Mark Stenhouse was granted Restricted Stock Units (RSUs) on May 19, 2026, with vesting contingent on continued service.

Summary

• Director Mark Stenhouse was granted 24,122 Restricted Stock Units (RSUs) on May 19, 2026.
• These RSUs were granted under the Issuer's Non-Employee Director Compensation Program.
• The RSUs will vest on the first anniversary of the grant date or the next annual stockholder meeting, provided Stenhouse continues to serve on the Board.
• Each RSU represents a contingent right to receive one share of Phathom Pharmaceuticals common stock.
• Following the transaction, Stenhouse beneficially owns 54,122 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Mark Stenhouse received a grant of 24,122 RSUs, indicating continued investment in the company's future by a board member.
• The RSUs are structured to vest over time, aligning the director's incentives with long-term company performance and shareholder value.
• The grant is part of a formal Non-Employee Director Compensation Program, suggesting a structured approach to director compensation.

Risks

• Vesting of RSUs is contingent on the Reporting Person's continuing service on the Board through the vesting date, implying a risk of forfeiture if service is terminated.
• The value of the RSUs is tied to the future performance of Phathom Pharmaceuticals' common stock, which is subject to market volatility and company-specific risks.

Future Outlook

The vesting of the RSUs is tied to future service and company performance, indicating a forward-looking incentive structure for the director.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common practice in the pharmaceutical and biotechnology sectors as a means to attract, retain, and incentivize experienced leadership aligned with long-term value creation.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns director incentives with long-term shareholder value, but the ultimate impact depends on the company's future stock performance.
• Employees: The compensation program for directors may set a precedent or standard for other compensation structures within the company.
• Management: Reinforces the company's commitment to retaining experienced leadership through equity-based compensation.

Next Steps

• Vesting of RSUs on the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.
• Reporting Person's continued service on the Board of Directors.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSUs, Stock Vesting, Beneficial Ownership